A study to evaluate the effectiveness of valsartan 320mg in combination with lisinopril 20mg versus monotherapy with lisinopril 40mg or valsartan 320mg in hypertensive patients with microalbuminuria on the reduction of urinary albumin creatinine ratio

Trial Profile

A study to evaluate the effectiveness of valsartan 320mg in combination with lisinopril 20mg versus monotherapy with lisinopril 40mg or valsartan 320mg in hypertensive patients with microalbuminuria on the reduction of urinary albumin creatinine ratio

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Valsartan (Primary) ; Lisinopril
  • Indications Essential hypertension; Hypertension
  • Focus Pharmacodynamics
  • Acronyms VALERIA
  • Sponsors Novartis
  • Most Recent Events

    • 16 Nov 2011 Actual patient number is 134 according to ClinicalTrials.gov.
    • 07 Nov 2011 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
    • 01 Sep 2008 Primary endpoint 'Urinary albumin:creatinine ratio' has been met. Results published in the Journal of Hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top